cognitive cybersecurity intelligence

News and Analysis

Search

The TCR-T cell therapies of tomorrow

Sweden’s fastest-growing private biotech, Anocca, has plans for clinical trials in pancreatic cancer using its VIDAR-1 TCR-T cell therapy. Since its inception, the company has raised €100m+ and has formed partnerships with EmendoBio and Shinobi Therapeutics. The company’s CEO, Reagan Jarvis, discusses the evolution of TCR-T therapy, the impact of AI, and their unique approach to treatments.

Source: www.labiotech.eu –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts

15 Best Patch Management Tools

Patch management tools are crucial for IT security and efficiency in 2025, automating software updates and security patches across various systems. Leading solutions include SolarWinds,